Veradermics Incorporated
Last updated September 27, 2026
Organization details
- Legal name
- Veradermics Incorporated
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New Haven
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MANE
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001827635
- EIN
- 84-3304423
Board of directors
-
Aaron Cowen · DirectorSince 2026
-
David Matthew Friedman · DirectorSince 2026
-
Jane M. Grant-Kels · DirectorSince 2026
-
John W. Childs · DirectorSince 2026
-
Katarina Pance · DirectorSince 2026
- Since 2026
-
Reid Alexander Waldman · Director · Chief Executive OfficerSince 2026
-
Vlad Coric · DirectorSince 2026
Chief executives
Reid Alexander Waldman
· Chief Executive Officer
Since February 2026
Board connections
6 of this board's directors also sit on 9 other boards.
- via Aaron Cowen and David Matthew Friedman
- via John W. Childs and Vlad Coric
- via Reid Alexander Waldman
- via David Matthew Friedman
- via Patrick G. Enright
- via Patrick G. Enright
- via Vlad Coric
- via Patrick G. Enright
- via Patrick G. Enright
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $54,092,449
- 26 purchases by 5 insiders
- Sold, last 12 months
- $103,119,917
- 15 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | David Hollander Officer (Chief R&D Officer) | Grant or award | +9,650 | — | — |
| Aug 20, 2026 | MONTANOVA CAPITAL, LLC Director | In-the-money exercise | +149,000 | — | — |
| Aug 20, 2026 | MONTANOVA CAPITAL, LLC Director | In-the-money exercise | +151,000 | — | — |
| Aug 19, 2026 | MONTANOVA CAPITAL, LLC Director | Open-market sale | −690,601 | $107.25 | $74,066,957 |
| Aug 19, 2026 | MONTANOVA CAPITAL, LLC Director | Open-market sale | −59,399 | $107.25 | $6,370,543 |
| Aug 17, 2026 | Durso Timothy August Officer (Chief Technical Officer) | Option exercise | +3,452 | $12.19 | $42,080 |
| Aug 17, 2026 | Reid Alexander Waldman Director, Officer (Chief Executive Officer) | Option exercise | +3,452 | $12.19 | $42,080 |
| Aug 17, 2026 | Durso Timothy August Officer (Chief Technical Officer) | Open-market sale | −7,918 | $106.71 | $844,930 |
| Aug 17, 2026 | Reid Alexander Waldman Director, Officer (Chief Executive Officer) | Open-market sale | −11,527 | $106.72 | $1,230,161 |
| Aug 17, 2026 | Durso Timothy August Officer (Chief Technical Officer) | Open-market sale | −16,306 | $107.52 | $1,753,221 |
| Aug 17, 2026 | Reid Alexander Waldman Director, Officer (Chief Executive Officer) | Open-market sale | −25,234 | $107.53 | $2,713,412 |
| Aug 17, 2026 | Durso Timothy August Officer (Chief Technical Officer) | Open-market sale | −16,767 | $108.38 | $1,817,207 |
| Aug 17, 2026 | Reid Alexander Waldman Director, Officer (Chief Executive Officer) | Open-market sale | −27,490 | $108.45 | $2,981,291 |
| Aug 17, 2026 | Durso Timothy August Officer (Chief Technical Officer) | Open-market sale | −2,348 | $109.34 | $256,730 |
| Aug 17, 2026 | Reid Alexander Waldman Director, Officer (Chief Executive Officer) | Open-market sale | −3,000 | $109.38 | $328,140 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.